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Abstract
Neuropilins, initially characterized as neuronal receptors, act as co-receptors for cancer related growth factors and were
recently involved in several signaling pathways leading to cytoskeletal organization, angiogenesis and cancer progression.
Then, we sought to investigate the ability of neuropilin-2 to orchestrate epithelial-mesenchymal transition in colorectal
cancer cells. Using specific siRNA to target neuropilin-2 expression, or gene transfer, we first observed that neuropilin-2
expression endows HT29 and Colo320 for xenograft formation. Moreover, neuropilin-2 conferred a fibroblastic-like shape to
cancer cells, suggesting an involvement of neuropilin-2 in epithelial-mesenchymal transition. Indeed, the presence of
neuropilin-2 in colorectal carcinoma cell lines was correlated with loss of epithelial markers such as cytokeratin-20 and E-
cadherin and with acquisition of mesenchymal molecules such as vimentin. Furthermore, we showed by surface plasmon
resonance experiments that neuropilin-2 is a receptor for transforming-growth factor-b1. The expression of neuropilin-2 on
colon cancer cell lines was indeed shown to promote transforming-growth factor-b1 signaling, leading to a constitutive
phosphorylation of the Smad2/3 complex. Treatment with specific TGFb-type1 receptor kinase inhibitors restored E-
cadherin levels and inhibited in part neuropilin-2-induced vimentin expression, suggesting that neuropilin-2 cooperates
with TGFb-type1 receptor to promote epithelial-mesenchymal transition in colorectal cancer cells. Our results suggest a
direct role of NRP2 in epithelial-mesenchymal transition and highlight a cross-talk between neuropilin-2 and TGF-b1
signaling to promote cancer progression. These results suggest that neuropilin-2 fulfills all the criteria of a therapeutic target
to disrupt multiple oncogenic functions in solid tumors.
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Introduction
Neuropilins (NRPs) are transmembrane non-tyrosine kinase
glycoproteins originally described in the nervous system. Neuro-
pilin (NRP) family consists of two genes, neuropilin-1 (NRP1) and
neuropilin-2 (NRP2). During nervous system development, NRP1
and NRP2 play a critical role in axon retraction and guidance
by binding class III semaphorins [1]. Initially characterized as
neuronal receptors, NRPs were also found to be expressed in
endothelial cells and subsequently were shown to play a role in the
development of the vascular system [2].
NRPs display a short intracytoplasmic tail which does not
contain a kinase domain. Initial investigations of neuropilin-depen-
dent molecular pathways suggested that neuropilins can not directly
transmit intracellular signals. This led to the proposal that hetero-
dimerization with other receptors are required to mediate neuro-
pilin-downstream signaling. One of these co-receptor complexes
described so far involves vascular endothelial growth factor receptor
(VEGFR) [3,4,5]. Besides the amplification of VEGFR signaling,
NRPs might interact with plexins to mediate class 3 semaphorin
signal transduction via Rho-related G proteins, modulating cyto-
skeleton organization [6].
Nevertheless, a highly conserved amino-acid sequence promot-
ing NRPs intracellular tail binding to the PDZ domain of GAIP-C
terminus interacting protein-1 (GIPC-1) was recently reported
suggesting the possibility that NRPs might regulate alternative
biological functions [7].
The multiple functions of NRPs were recently highlighted by
the identification of NRP role in oncogenesis. Besides the presence
of NRPs on tumor-associated vessels, NRPs were expressed by a
large variety of tumors, suggesting a potential role of this glyco-
protein in cancer progression. Indeed, NRP2 expression was found
in osteosarcoma [8], melanoma [9], lung cancers [10,11], brain
tumors [12,13] colon cancers [14], pancreatic cancers [15,16,17],
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carcinoma [20], infantile hemangioma [21], ovarian neoplasms
[22] and bladder cancers [23]. In colon carcinoma, NRP2 directly
promotes tumor progression in a cell autonomous manner (see
review of NRP2 expression on cancer cells in Table S1). It was
suggested that NRP2 oncogenic properties rely on an increased
VEGFR1 phosphorylation and an activation of the VEGFR1/
Pi3K/Akt signaling. [14] However, the precise molecular
pathways driven by NRP2 and involved in oncogenesis remain
largely unknown.
Epithelial-mesenchymal transition (EMT) is one of the major
molecular mechanisms carried out during oncogenesis to promote
cancer progression. EMT is characterized by a breakdown of cell
junctions, the loss of epithelial characteristics and cell polarity,
contributing to carcinoma progression. Besides the gain of mesen-
chymal markers, EMT endows cancer cell for migration, invasive-
ness and subsequent metastasis formation [24]. Despites several
studies pertaining to the role of NRP2 in cancer progression, no
substantial evidence established an involvement of this molecular
pathway in EMT.
Here, we used colon cancer cell lines transfected with NRP2
transgene or siRNA to investigate NRP2 involvement in EMT.
These experiments provided evidence that NRP2 endows colon
cancer cell lines for colony and xenograft formation. Moreover, a
conversion from epithelial to fibroblast-like shape was triggered by
NRP2 expression, as well as the acquisition of vimentin and EMT
specific transcription factors. Then, we examined the influence of
NRP2 on transforming growth factor b1 (TGF-b1) signaling that is
believed to contribute to the late-stage carcinoma by inducing
EMT. We showed that NRP2 promotes a constitutive Smad2/3
phosphorylation in colon cancer cell lines. Moreover, specific
siRNA targeting NRP2 or treatment with pharmacological inhi-
bitors of TGFb-1 type 1 receptor (TGFbRI) prevented Smad2/3
phosphorylation and the NRP2-mediated EMT of colorectal can-
cer cells. Collectively, these results suggest that NRP2 cooperates
with TGFbRI to promote EMT in colorectal carcinoma.
Materials and Methods
Cell culture
Human cell lines HT29, Colo320, SW620, MCF7, Caki, A498,
HEK293 were purchased from the American Type Cell Culture
Collection and were cultured in RPMI1640 or DMEM (Lonza,
Paris, France) supplemented with 10% heat inactivated endotoxin
free fetal calf serum (FCS), (Invitrogen, Cergy-Pontoise, France).
Bes-PAC01, Bes-PAC03, Bes-PAC04 and Bes-PAC05 (Pancreatic
Adeno-Carcinoma) cell lines were originally isolated from ascitic
fluids derived from four patients with pancreatic adenocarcino-
mas, in our university hospital. R3III cell line was kindly provided
by Nathalie Labarriere, Inserm (Nantes, France). Jijoye and Raji
cell lines (Human Burkitt Lymphoma) were provided by Diaclone
(Besanc ¸on, France). Cell lines used in this study were authentified
using DNA profiling (short tandem repeats analysis), in line with
ATCC’s recommendations (see Table 1). Short tandem repeat
(STR) analysis is a molecular biology method recommended for
cell line identification. Cell lines used in this study were genotyped
before freezing and every two months. STR analysis was per-
formed with the AmpFISTR Identifiler PCR Amplification Kit
(Applied Biosystems). Height specific loci including tandem repeats
on DNA from cancer cell lines were analyzed. STR analysis
measures the exact number of repeating units for each allele
(D7S820 8,20 means that 8 and 20 repeats are identified on each
allele of the D7S820 locus for the cell line Jijoye). If a variant
appears that contains a partial repeat, that partial repeat unit is
designated by a decimal followed by the number of bases in the
partial repeat.
pcDNA Expression plasmids
The influence of NRP2 on colon cancer cell progression was
assessed by transferring NRP2 gene in the HT29 cell line. We
generated HT29
NRP2 cell lines using two expression plasmids
encoding hNRP2 (pcDNA3.1-NRP2, kindly provided by M.
Klagsbrun) and pCMV6-XL5-NRP2 (purchased from Origene
(Rockville, MD, USA). Control HT29 cells were generated using
pcDNA3.1 or pCMV6-XL5 vectors. 1.5610
6 HT29 cells were
seeded in a 60 mm
3 flask in 4 mL medium and incubated for
24 h. Then, cells were stably transfected with 1 mg of pcDNA3.1-
NRP2 or pCMV6-XL5-NRP2 expression vectors or control vec-
tors using the Effectene kit (Qiagen, Courtaboeuf, France) according
to the manufacturer’s instruction. Cells transfected with pcDNA3.1
vectors were selected with 0.8 mg/mL of geneticin (Invitrogen,
Cergy-Pontoise, France), 48 h following the transfection.
Small Interfering RNA
Using the Ambion siRNA web design tool, we identified one
potential NRP2-specific target sequence. Specific NRP2 siRNA
(sense 59-AAA GGC TGG AAG TCA GCA CTA ATT T-39 and
anti-sense 59-AAA AAT TAG TGC TGA CTT CCA GCT T-39)
Table 1. DNA STR (Short Tandem Repeats) profiling of tumor cell lines.
D7S820 CSF1PO TH01 D13S317 D16S539 vWA TPOX D5S818
Jijoye 8,10 10,11 7,9 12 10,11 15,19 6,8 12
SW620 8,9 13,14 8 12 9,13 16 11 13
Caki-1 8,12 10,11 6,8 11,12 12 15,17 8,11 11,12
MCF-7 8,9 10 6 11 11,12 14,15 9,12 11,12
A498 10,11 11,12 6, 9.3 12 12 18 8,11 11,13
Colo320 9,12 11 8,9 11 11,12 15,18 8,9 12
HT29 10 11,12 6,9 11,12 11,12 17,19 8,9 11,12
5637 10,11 11 7,9 11 9 16,18 8,9 11,12
HEK293 11,12 11,12 7,9.3 12,14 9,13 16,19 11 8,9
MDAMB231 8,9 12,13 7,9.4 13 12 15,18 8,9 12
Raji 10 10,12 6,7 13 8,11 16,19 8,13 10,13
doi:10.1371/journal.pone.0020444.t001
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TTGG-39 and anti-sense 59-AAAACCAACGTGGCATGCCCC-
TC-39) sequences were annealed and cloned into the BbsI site of
the 39 LTR of pFIV-H1/U6 vector according to manufacturer’s
instructions (System Biosciences, Mountain View, CA). Sequences
were confirmed by NIH BLAST analysis to have no substan-
tial homology to sequences in other vertebrate genes. Lentiviral
supernatant production and subsequent infection of cells were per-
formed according to manufacturer’s instructions (System Biosci-
ences, Mountain View, CA). Colo320 stably transfected were
selected with 3 mg/mL of puromycin (Invitrogen, Cergy-Pontoise,
France), 48 h following the transfection.
Flow cytometry
Anti-NRP2, anti-NRP1, anti-pSmad2/3, anti-TGFb1, anti-
TGFbR1 were from Santa-Cruz Biotechnology (Heidelberg, Ger-
many). Anti-smad2/3 and anti-TGFRII, were from RD system
(Lille, France). Alexafluor488-labelled secondary antibodies were
purchased from Fluoprobes (Interchim, Montluc ¸on, France). Ten
thousands cells from each sample were evaluated for fluorescence
detection using BD FACSCanto cytometer. (Becton Dickinson, Le
Pont de Claix, France) For intracellular staining, cells were fixed
for 20 min at 4uC in 2% paraformaldehyde. Staining was then
realized at room temperature for 30 min in a buffer containing
0.4% saponin and 5% FCS. Wash buffer contained 0.1% saponin,
5%FCS. For flow cytometry analysis, Relative Fluorescence Inten-
sity (RFI) was calculated.
Cell Proliferation Assay
Cell proliferation in vitro was analyzed with the tetrazolium
salt 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide
(MTT). Briefly, 4000 cells per well were seeded in 96-well micro-
plates containing 100 mL of medium per well. For analysis, 10 mL
of MTT substrate (of a 5 mg/mL stock solution in phosphate-
buffered saline) was added to each well, and the plates were let to
standard tissue incubator conditions for an additional 2 hours.
Cells were solubilized in 200 mL of dimethyl sulfoxide, and colori-
metric analyses were performed (wavelength, 570 nm). The plates
were assayed every 24 hours for next 3 consecutive days.
ELISA assay
Cells were incubated in RPMI or DMEM-1% FCS for 24 h.
Then cells were counted and 10000 cells per well were seeded in
96-microplate in 200 mL DMEM-0.1% FCS for 24 h. VEGF
production was assessed on supernatants using human VEGF Elisa
kit (Strathmann Biotec, Hamburg, Germany).
Flow Cytometry Analysis of DNA Content
Cells were harvested by trypsinization, washed with ice-cold
PBS, fixed in 70% ethanol. Prior to DNA analysis, cells were
stained with 50 mg/mL propidium iodide (Sigma-Aldrich, Lyon,
France) and 2 mg/mL DNase-free RNase (Sigma-Aldrich, Lyon,
France) for 15 min at 37uC in the dark. DNA content was
measured using a FACSCalibur flow cytometer (Becton Dick-
inson, Le Pont de Claix, France) and analyzed with the CellQuest
program.
Xenograft experiments
Nude mice were obtained from Janvier (Le Genest St Isle,
France), and maintained in our animal facility according to the







cell lines resuspended in 100 mL of PBS were inoculated
subcutaneously in nude mice and tumor growth was monitored
biweekly in each group. Tumor volume was calculated by the
formula V=1/2a6b
2, where a is the longest tumor axis, and b is
the shortest tumor axis. When tumors reached 1 cm in diameter,
mice were sacrificed and tumors were fixed in formol for
subsequent immunohistochemical analysis.
Colony formation assay
Effect of NRP2 expression on colony formation in vitro was
evaluated by soft agar colony-formation assay. 5000 cells per well
were seeded in 500 mL of 2% agarose medium in a 24-well plate.
Cells were incubated at 37uC, 5% CO2 and photos were taken
after 10 days of culture.
Invasion assay
Invasion was evaluated using 96W QCM Invasion Assay
(Millipore, USA). Briefly, equal number (100000) of control cells
(HT29
ctrl) or NRP2 expressing cells (HT29
NRP2) resuspended in
serum-free medium were placed in the top compartment of a
standard 8 mM pore Boyden chamber. Feeder tray wells contained
serum free medium or medium 10% FCS. Following 16 hours
invasion (37uC, 5% CO2), invasive cells were incubated with cell
detachment buffer, lysed and marked with CyQuant GR dye.
(QCM 96W Assay, Millipore, International). Fluorescence was
then evaluated with a fluorescence plate reader (Cell Lab Quanta,
Beckman-Coulter) using a 480–520 nm filter set.
Cell Treatments
TGF-b1 signaling was inhibited using SD-208 or SB-431542
(TGFRI kinase inhibitor) diluted in DMSO (Sigma-Aldrich, Lyon,
France). DMSO served as control medium in all experiments. In
some experiments Avastin (Pharmacy of CHU Jean Minjoz,
Besanc ¸on, France) was used to inhibit VEGF-A. TGF-b1 was
purchased from RD System (Lille, France).
Western Blot analysis
Briefly, after two washing steps, cells were harvested and
solubilized in lysis buffer containing1 mM EDTA, 1 mM NaF,
1 mM Vanadate and one complete Mini protease Inhibitor
Cocktail Tablet (Complete Mini EDTA Free, per 10 mL of lysis
buffer, Roche, France). 30 mg of whole-cell lysates were separated
by sodium duodecyl sulfate-polyacrylamide gel electrophoresis and
transferred to polyvinylidene difluoride membranes by electro-
blotting. The blots were then blocked for 1 h in 5% milk before
incubation with specific antibodies as follows: anti-NRP2 and
anti-twist1 (Santa Cruz Biotechnology, Heidelberg, Germany),
anti-Smad2/3 (R&D System, Lille, France), anti-vimentin, anti-
Ecadherin, anti-TGFb1, anti-smad2/3, anti-pSmad2, anti-snail
(all from Cell Signaling Technology, Danvers, USA). All anti-
bodies were diluted in Trisbuffered saline and 0.1% (v/v) Tween-
20 containing dried milk. Blotted proteins were detected and
quantified on a bioluminescence imager and BIO-1D advanced
software (Wilber-Lourmat, Marne-la-Valle ´e, France), after incu-
bating blots with a horseradish peroxidaseconjugated appropriate
secondary antibody (Beckman Coulter, Paris). For some experi-
ments, cytoplasm and nuclear subcellular fractions were harvested
after differential centrifugation in adapted buffers; the presence or
absence of subcellular specific proteins (such as b-actin or histone
H1) attested to subcellular separation.
Co-immunoprecipitation analysis
Cells were lysed in PBS containing 200 mM of TRIS-Hcl
pH 7.4, 100 mM Nacl, 1% v/v tritonX100, 1 mM DTT, 15 mM
NRP2 Role in Epithelial to Mesenchymal Transition
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protease Inhibitor Cocktail Tablet (Complete Mini EDTA Free,
per 10 mL of lysis buffer, Roche, France). Rabbit anti-TGFRI
polyclonal antibodies (Santa-Cruz Biotechnology) and Rabbit IgG
polyclonal antibodies were added to the lysates at a final dilution of
1/100 and incubated overnight at 4uC. Protein-G magnetic beads
(Invitrogen, Cergy-Pontoise, France) were added to the mix and
incubated for additional two hours at 4uC. Proteins were then
eluted by magnetic separation and denaturated. Western-Blot was
then performed using anti-NRP2 antibody (Santa Cruz Biotech-
nology, Heidelberg, Germany).
Histopathologic Analysis and Immunohistochemical
Staining of Tissues
Tissue samples, obtained from xenografts were fixed in 4%
formalin and paraffin embedded. Then, blocks were cut serially at
4-mm thickness. HES (Hematoxyline Eosine Safran) staining was
used to assess morphology. A standard immunohistochemical
technique was performed using a Ventana BenchMark XT (Ven-
tana Medical Systems, Inc., Tucson, Arizona) immunostainer with
the following primary antibodies: anti E-cadherin (Zymed, San-
Francisco, USA), anti-cytokeratin-20 (Zymed, San-Francisco,
USA).
Surface Plasmon Resonance analysis
Design and fabrication of homemade chips compatible with
SPR (Surface Plasmon Resonance) have been performed as
previously published with the help of the MIMENTO technolog-
ical platform, Besanc ¸on, France [25]. The NRP2 chips fabricated
in this study consist in the covalent grafting of Fc-NRP2 entities on
chemically activated self assembled monolayer following the
procedure of protein chip building recently published [26]. Fc-
NRP2 were from RD System (Lille, France). This procedure leads
to a coverage of 7.4 +/2 0.1 femtomole/mm
2 of NRP2. Injections
of BSA (Control 2), VEGF (Control +) and TGFb1 are performed
at 250 nM in PBS-Tween 0.05%, pH 7.4. Biacore experiments
were performed with the Biacore 2000 apparatus at 25uC with a
flow rate comprise between 2 and 30 ml/min.
Real Time-quantitative PCR (RT-qPCR)
Total RNA were extracted using Kit RNeasy mini (Qiagen,
Courtaboeuf, France) and reverse transcribed using random
hexamers and Moloney murine leukemia virus reverse transcrip-
tase (Life Technologies, Rockville, MD, USA). Duplicate samples
were subjected to RT-qPCR. mRNA were quantified using pri-
mers listed below: NRP2 (Hs00187290_m1), Snail1 (Hs00195-
5991_m1), TGF-b1 (Hs00171257_m1), Gli1 (Hs00171790_m1),
Twist1 (Hs00361186_m1) (Applied Biosystems).
ABL mRNA from each sample was quantified as an endog-
enous control of internal RNA. Relative mRNA expression was
calculated using the Delta-Delta-Ct method and untreated cells
were used as calibrator.
Slide preparation and confocal microscopy
Cells were spread onto Labteck chamber slides (Sigma-Aldrich,
Lyon, France) and subsequently treated with the appropriate
reagents. Cells were fixed in 4% paraformaldehyde and permea-
bilized with 0.1% Triton X100. After 20 minutes of blocking in
20% fetal bovine serum and washing, cells were stained with
appropriate antibodies Stacks of confocal images were collected
with an Olympus FV1000 laser scanning confocal microscope.
Cell nuclei were counterstained with DAPI (49,6-diamidino-2-
phenylindole). For fluorescence quantification, ratio of fluorescence
intensity was calculated in each condition. Ratio of fluorescence
intensity was calculated in dividing the nuclear fluorescence by the
cytoplasm-membrane fluorescence. Fluorescence intensity of 50
cells has been analyzed in each condition.
Smad reporter assay
We have used the TGF-b reporter assay from SABiosciences
(Qiagen, Courtaboeuf, France) for the quantification of TGF-b-
induced SMAD2/3 signaling. Quantification of the firefly lucif-
erase was realized using a Dual-Luciferase Reporter assay system
(Promega Co, Madison, USA) according to the manufacturer’s
protocol. All transfections were performed in triplicate using
Lipofectamine kit. (Invitrogen, Cergy-Pontoise, France). After
24 h of transfection, medium was changed and cells were treated
by 50 ng/mL of TGF-b1 for additional 24 hours. Results are
presented as the ratio between the firefly luciferase activity and the
renilla luciferase activity (Ren/Luc) for each conditions. Then, values
were reported to the values of the negative control.
Statistical analysis
Results are expressed as the mean plus or minus the standard
error of the mean (SEM). Group comparisons were performed
using Student t test. Differences were considered significant at
p,0.05.
Results
NRP2 expression in human cancer cell lines
We first sought to examine the expression of NRP2 glycoprotein
in various cancer cell lines. Immunofluorescence analysis con-
firmed that NRP2 is expressed at the membrane of several human
cancer cell lines (Figure 1A). Human umbilical vein endothelial
cells (HUVEC), isolated from normal human umbilical vein, were
used as a positive control for NRP2 expression. We observed
NRP2 expression at the membrane of 2 out of 3 colon cancer cell
lines (SW620, Colo320 but not HT29). NRP2 was also expressed
in all renal cancer cell lines tested (HEK 293, Caki, R3III and
A498), in two of four pancreatic cancer cell lines (Bes-PAC03 and
Bes-PAC04, derived from patient’s ascitic fluid in our institute), in
NCIH441 lung cancer cell line and in 5637 bladder cancer cell
line (Figure 1A). MDAMB231 breast cancer-cell line expressed
NRP2 whereas no NRP2 staining was found on Burkitt lymphoma
cells lines (Raji, Jijoye) (Figure 1A).
Immunohistochemistry studies were then undertaken to deter-
mine if NRP2 is expressed at the membrane of various paraffin
embedded-human cancer specimen. NRP2 was expressed on 3 out
of 10 colon carcinoma, 5 out of 15 breast carcinoma and 4 out of
12 pancreatic carcinoma. Of note, NRP2 was not detected on
prostate cancers (n=10) and B cell lymphoma (n=10) (data not
shown). Moreover, immunohistochemical staining showed that
NRP2 is expressed at the membrane of human colon carcinoma
and breast carcinoma while it is not expressed in non malignant
tissues (Figure 1B). Our results are concordant with previous
published reports. Indeed, in a recent study, Gray et al observed
that NRP2 was not detectable in nonmalignant colonic mucosa
but was evident in 10 (83%) of 12 adjacent colon adenocarcinoma
and in five (71%) of seven liver metastases by IHC staining.
Moreover, in another study, NRP2 expression was found in 5 out
of 6 (83%) commonly used pancreatic cell lines [15] and in 7 out of
11 (64%) surgical specimens of pancreatic adenocarcinoma by
IHC staining [14]. Finally, in breast cancer, Yasuoka et al reported
Nrp2 expression in 60 out of 113 invasive breast carcinoma
(53.1%) [18]. From these various studies, it appears that NRP2
seems to be specific of several tumor tissues, while no expression of
NRP2 Role in Epithelial to Mesenchymal Transition
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confirming that NRP2 is an attractive target for innovative anti-
tumor therapies (see Table S1 for review of NRP2 expression in
cancers).
To study the precise role of NRP2 in cancer progression, we
decided to generate colon cancer cell lines expressing or not NRP2,
using NRP2 gene transfer or NRP2 specific siRNA. Hence, NRP2
was transfected into HT29 and a specific siRNA was used to
knockdown NRP2 expression in Colo320. Flow cytometry experi-
ments were performed to confirm the modulation of NRP2
expression in HT29 and Colo320 (Figure 2A). No modulation
of NRP1 expression was observed in HT29 or Colo320 trans-
fected cells. Caki-1 renal cancer cells were used as positive con-





siRNA-NRP2 was controlled by western
blotting (Figure 2B).
NRP2 promotes tumor proliferation
We took advantage of the previous cell lines to study the role of
NRP2 on cancer proliferation in vitro and tumor growth in vivo.
Proliferation was monitored using MTT assays. HT29
NRP2 cells
showed a superior proliferation rate at 24, 48 and 72 h compared
to HT29
ctrl (Figure 2C). Conversely, NRP2 knockdown using
specific siRNA, negatively modulated the proliferation of Colo320
tumor cell line (Figure 2C). These experiments showed that NRP2
expression enhances colon cancer cell line proliferation in vitro
(the significativity at each time point of these MTT assays is
indicated in Table S2). To confirm the influence of NRP2 on cell






siRNA-NRP2 cancer cells. NRP2 expressing cells HT29
NRP2
and Colo320
siRNA-ctrl had a doubling time of 8 and 11 hours
respectively, whereas doubling times of NRP2 lacking cells
HT29
ctrl and Colo320
siRNA-NRP2 were 13 and 14 hours. Since
NRPs are VEGF co-receptors, we monitored VEGF-A production
in HT29 and Colo320 cultures by Elisa test. These cells produced
low levels of VEGF-A. NRP2 expression did not influence VEGF
production (Figure S1). Moreover, the neutralizing mAb bevaci-
zumab, known to inhibit the proliferation of microvascular endo-
thelial cell line HMEC-1 [27], was used to address the potential
role of VEGFA in NRP2-mediated tumor cell growth. These
experiments showed that VEGFA neutralization did not influence
NRP2-mediated HT29 or Colo320 proliferation. (Figure 2D)
Moreover, NRP2 is a functional receptor for semaphorin 3F,
which was described as an inhibitor of angiogenesis, tumor pro-
gression and metastasis [28]. Western blotting experiments showed
that HT29
ctrl and HT29
NRP2 express the same level of semaphorin
3F, whereas no semaphorin 3F was found in Colo320 cells,
suggesting that NRP2-mediated tumor proliferation does not
involve semaphorin 3F (Figure S2). Then, the distribution of the
Figure 1. Neuropilin-2 expression on human cancer cells. A, Flow cytometry analysis of NRP2 expression in human cancer cell lines. B,
Immunohistochemical staining of NRP2 in human colon tissues and breast tissues (brown). Formalin-fixed paraffin-embedded tissues were incubated
overnight at room temperature with anti-human NRP2 antibody. Representative micrographs were taken at an original magnification x1000; NRP2 is
expressed at the membrane of human colon and breast carcinomas while it is not expressed in healthy tissues.
doi:10.1371/journal.pone.0020444.g001
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NRP2 expression was associated with an enhanced number of cells
in phase S (Figure 2E). Serum deprivation in culture medium
induced an increase in the subG1 fraction only in NRP2 negative
conditions (data not shown). Collectively, these results showed that
NRP2 expression in colorectal cell carcinoma promotes cancer cell
proliferation and survival.
NRP2 ablation using siRNA inhibits xenograft formation
The precise role of NRP2 on cancer progression was first
characterized in vivo. To examine the effect of NRP2 expression on




ctrl subcutaneously into nude mice.
Tumor incidence and volume were assessed biweekly. Tumors
appeared in all mice inoculated with HT29
ctrl and HT29
NRP2.
NRP2 significantly enhanced tumor growth in vivo (Figure 3A).
To confirm these results, we decided to investigate if NRP2
targeting using specific siRNA could inhibit tumor formation.
While 1.10
6 Colo320
siRNA-ctrl cells injected subcutaneously into
nude mice induced tumor engraftment in all mice, NRP2
inhibition using specific siRNA prevented Colo320 engraftment
in all animals suggesting a critical role of NRP2 in the early events
contributing to tumor formation (Figure 3B).The influence of
NRP2 inhibition using specific siRNA on Colo320 tumorigenicity
was confirmed in vitro. For this purpose, Colo320 cells were treated
with NRP2 siRNA or ctrl siRNA and cultured in a soft agar assay.
NRP2 knockdown in Colo320 decreased the number of colonies
observed in soft agar experiments (Figure 3C). Since HT29 did not
form colonies in soft agar cultures, we decided to investigate the
influence of NRP2 on HT29 invasion and migration. For this
purpose, a Boyden chamber assay was performed to quantify
HT29 invasiveness according to NRP2 expression. The capacity of
HT29 cells to migrate through the matrigel-coated filter was
significantly enhanced in the presence of NRP2 (Figure 3D).
Similar results were observed with Colo320 (data not shown). Of
Figure 2. Neuropilin-2 promotes cell proliferation in colon carcinoma cell lines. Transfected cells were analyzed for NRP1 and NRP2
expression by flow cytometry analysis (A) or by western blotting (B). For flow cytometry analysis, Relative Fluorescence Intensity (RFI) was calculated.
Caki1 and HUVEC cells were used as positive control for NRP1 and NRP2 staining respectively. C, Proliferation of HT29 and Colo320 cells, according to
NRP2 expression was assessed using MTT assays. 4000 cells were let in culture during 24, 48 or 72h before analysis. NRP2 expression is associated with
an enhanced proliferation in colon cancer cells. Data represent means of triplicates plus or minus the standard error (SE) of a representative
experiment out of three performed. (**, P,0.01). D, Similar MTT experiments were reproduced in the presence of bevacizumab (0.25 and 1 mg/mL,
72 h). HMEC-1 microvascular endothelial cells were used as a positive control for the bioactivity of bevacizumab. Indeed, bevacizumab significantly
decreases HMEC-1 proliferation whereas no decrease of cell proliferation is observed with HT29
NRP2 and Colo320 cancer cells. Experience was made 3
times, and for each time in triplicates. E, Flow cytometric analysis of DNA content of transfected colon cancer cells. NRP2 expression is associated with
an enhanced number of cells in phase S. Data represent results of a representative experiment out of 3 expressed as the mean of duplicate assays
(*, P,0.05; **, P,0.01, ***P,0.001).
doi:10.1371/journal.pone.0020444.g002
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suggesting an autonomous effect of NRP2 on the invasive pro-
perties of HT29 cells.
NRP2 induces epithelial-mesenchymal transition
The cell autonomous effect of NRP2 on HT29 invasiveness
led us to explore the direct impact of NRP2 on EMT. The
phenomenon of EMT is defined by the transition of epithelial cells
to fibroblastoid- or mesenchymal-like cells. EMT is an important
mechanism associated with cancer invasiveness and metastasis
formation. In a recent paper, NRP1 was found to drive EMT
process by promoting Snail1 nuclear localization in prostate can-
cer cells [29]. In culture, NRP2 transfection conferred to HT29 a
fibroblastic-like shape reminiscent of mesenchymal cells, whereas
HT29 and HT29
ctrl cell lines displayed a cuboidal appearance,
formed clusters which progressively increased in number, and
closely apposed cell-to-cell junctions typical of epithelial cells
(Figure S3A). This observation prompted us to investigate the
ability of NRP2 to orchestrate the EMT.
EMT is characterized by the loss of epithelial markers and
acquisition of mesenchymal components. E-cadherin, occludin
and cytokeratin are downregulated during EMT, while N-
Figure 3. NRP2 enhances colorectal cancer xenograft formation. A, 1.10
6 HT29
ctrl and HT29
NRP2 cells were injected subcutaneously in nude
mice (15 mice in each group included in four independent experiments). NRP2 significantly enhanced tumor growth of colon cancer cells in xenograft
experiments. Tumor volume was calculated by the formula V=1/2 a 6b
2, where a is the longest tumor axis, and b is the shortest tumor axis. Data




siRNA-ctrl were injected s.c in nude mice (15 mice in each group included in four independent experiments). Mice receiving Colo320
siRNA-NRP2
did not develop tumor, even after 2 months. Data represent results of a representative experiment out of 3. C, 5000 Colo320 cells treated with control
siRNA or NRP2 siRNA were cultured in soft Agar containing medium during 10 days. Colonies were then photographed (magnitude*10) and counted.




NRP2 were resuspended in serum-free medium and placed in the top compartment of a standard 8 mM
pore Boyden chamber. Following 16 hours of culture (37uC, 5% CO2), invasive cells were incubated with cell detachment buffer, lysed and marked
with CyQuant GR dye. Fluorescence was then evaluated with a fluorescence plate reader using a 480-520 nm filter set.
doi:10.1371/journal.pone.0020444.g003
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is a universal epithelial marker that plays a key role in epithelial
integrity maintenance. Loss of its expression is a hallmark of EMT.
Vimentin is a canonical marker for detecting fully transitioned
epithelial cells and their acquisition of fibroblastoid-like pheno-
type. Accordingly, we assessed the pattern of E-Cadherin and
vimentin expression in colorectal cancer cell lines by western-
blotting. The presence of NRP2 in HT29 completely abrogated
the expression of E-Cadherin and induced the production of
vimentin. (Figure 4A). This observation was confirmed in Colo320
where specific disruption of NRP2 using siRNA down-regulated
vimentin (Figure 4A). Then we analyzed the expression of EMT-
associated markers in HT29
ctrl and HT29
NRP2 xenografts. Immu-
nohistochemical analysis revealed that the presence of NRP2 on
HT29 was associated with an invasive phenotype. While HT29
ctrl
xenografts reconstituted the morphology of moderate differentiat-
ed colon adenocarcinoma, HT29
NRP2 induced less differenti-
ated xenografts displaying an invasive phenotype (Figure 4B).
HT29
NRP2 xenografts lacked epithelial markers such as cytoker-
atin-20 and E-cadherin compared to HT29
ctrl xenografts (Figure 4B).
In order to confirm that NRP2 expression is associated with a
mesenchymal phenotype, we have determined NRP2, E-cadherin
and vimentin levels in four renal and pancreatic cell lines by
western-blotting. We observed that NRP2 expression is correlated
with vimentin expression and with a lack of E-cadherin expression
in these cancer cell lines. (Figure 4C)
Of note, NRP2 transfection in HT29 also led to the decrease of
EpCAM (epithelial cell adhesion molecule) in HT29 cells (Figure
S3B). We could also observe an inverse correlation between NRP2
and Epcam in several pancreatic cancer cell lines (Figure S3C),
confirming that NRP2 is quite associated with a mesenchymal
phenotype of cancer cells. Several zinc-finger transcriptional




siRNA-ctrl were analyzed for expression of
epithelial and mesenchymal markers (respectively E-Cadherin and vimentin) by western-blotting (whole cell lysate). b-actin was used as a control of
protein loading. The presence of NRP2 decreases E-cadherin expression and induces vimentin in HT29 colorectal cancer cells. Specific disruption of
NRP2 using siRNA down-regulated vimentin in Colo320 cancer cells. Blotted proteins have been quantified with the BIO-1D advanced software and
reported to the b-actin level. B, Frozen sections of the isolated tumors from HT29
ctrl and HT29
NRP2 xenografts were subjected to
immunohistochemical staining with anti-cytokeratin-20, anti-Ecadherin antibodies and HES staining (magnification x100). HES (Hematoxiline Eosine
Safran) staining was used to assess morphology. HT29
NRP2 invade smooth muscle (sm=smooth muscle) as indicated by arrows unlike HT29
ctrl which
showed a local invasion. HT29
NRP2 xenografts lacked epithelial markers such as cytokeratin-20 and E-cadherin. C, Pancreatic and renal cancer cell lines
were analyzed for NRP2, E-cadherin and vimentin expression by western-blotting. b-actin was used as a control of protein loading. The presence of
NRP2 is positively correlated with mesenchymal marker vimentin and inversely correlated with epithelial marker E-cadherin. D, Transcriptional factors




siRNA-ctrl whole cell lysates by western-blotting. NRP2 expressing
cells (Colo320
siRNA-ctrl and HT29
NRP2) have increased levels of Snail1 and Twist1 compared to NRP2 lacking cells (HT29
ctrl and Colo320
siRNA-NRP2). b-
actin was used as a control of protein loading. Blotted proteins have been quantified with the BIO-1D advanced software and reported to the b-actin
level. E, Evaluation of NRP2, Snail, Twist1, Gli1 and TGFb1 expression by QRT-PCR analysis in Colo320
siRNA-ctrl and Colo320
siRNA-NRP2. Decreased NRP2
expression is indeed associated with a down-regulation of transcriptional regulators Snail, Gli1 and twist1 and with a decreased TGF-b1 production. F,
Confocal microscopy analysis of localization of b-catenin. Cells (HT29
ctrl and HT29
NRP2) were stained with DAPI (blue) for nuclear staining and also
with anti-b-catenin antibody (green). Whereas b-catenin (green) is localized at the membrane in HT29
ctrl cells, HT29
NRP2 cells show a nuclear
localization of this transcriptional activator.
doi:10.1371/journal.pone.0020444.g004
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which is the master repressor of E-cadherin [31], but also Twist
[32]. Gli family members are zinc-finger transcription factors,
which are involved in embryogenesis and carcinogenesis. Hedge-
hog-Gli signaling axis has been recently proposed as a regulator of
EMT process through interactions with TGF-b1 pathway [33].
Then, the next set of experiments was performed to analyze EMT-
related transcription factors in HT29 and Colo320 cell lines,
according to NRP2 expression. Western-Blot experiments showed
an increase of Twist and Snail in HT29
NRP2 in comparison to
HT29
ctrl. (Figure 4D) Conversely, NRP2 targeting using speci-
fic siRNA in Colo320 led to a decreased expression of these
transcription factors, as shown in western blotting experiments
(Figure 4D). Of note, the influence of NRP2 on EMT-related
transcription factors was confirmed at the RNA level. Indeed,
expression of these transcriptional regulators of EMT was ana-
lyzed by real-time quantitative PCR in Colo320
siRNA-ctrl and
Colo320
siRNA-NRP2. Decreased NRP2 expression was associated
with a down-regulation of Snail1, Twist1 and Gli1 transcription
(Figure 4E). Moreover, since nuclear accumulation of the tran-
scriptional activator b-catenin is a hallmark of EMT in cancer cells
[34], we decided to evaluate localization of this protein in HT29
ctrl
and HT29
NRP2 by confocal microscopy. Whereas b-catenin is
localized at the membrane in HT29
ctrl cells, HT29
NRP2 cells show
a nuclear localization of this transcriptional activator. (Figure 4F)
Furthermore, TGF-b1 is a Janus-like cytokine and has been de-
monstrated to play a pivotal role in EMT [35,36]. The expression
of TGF-b1 was then monitored in our various colorectal cancer
cell lines. We observed that NRP2 knock-down in Colo320
decreased TGF-b1 production (Figure S4) while NRP2 expression
in HT29 was associated to a constitutive production of TGF-b1.
(Figure S4) Altogether, these results identified a direct role for
NRP2 on EMT promotion in colorectal cancer cells.
Regulation of TGF-b1 pathway by NRP2
Next, we investigated the influence of NRP2 on TGF-b1
signaling. In response to ligand binding, type I and II TGF-b
receptors (TGFRI, TGFRII) form tight complexes leading to
phosphorylation of Smad2 and Smad3. Phosphorylated Smads
interact with cytoplasmic Smad4 and translocate into the nucleus
where Smad complex control transcription of target genes. A
recent study suggested that NRP1 can be a co-receptor for both
active TGFb1 and TGFb1-LAP [37]. Moreover, NRP1 associates
with TGFRI and TGFRII to enhance TGFb1 signaling in cancer
cells, augmenting canonical Smad2/3 signaling [38]. A peptide of
the b2 domain of NRP1 (RKFK, similar to a thrombospondin-1
peptide, (also present in NRP2) activates the latent form of TGF-
b1 [37]. Moreover, in fibroblastic cells, NRP1 upregulates TGFb1
pathway by enhancing smad2/3 phosphorylation and promotes a
myofibroblast phenotype [39]. Then, considering the potent
promoter effect of NRP1 on TGFb-1 pathway and on EMT, we
hypothesized that NRP2 might have similar properties.
Hence, we first assessed Smad2/3 activation status according
NRP2 expression in HT29 and Colo320. Using flow cytometry
and western blot experiments, we observed that NRP2 expression
is associated to a constitutive smad2/3 phosphorylation (Figure 5A
and B). While exogenous TGF-b1 was mandatory for smad2
phosphorylation detection in HT29 using western blotting experi-
ments, we could observe that Smad2 was constitutively phosphor-
ylated in HT29
NRP2 cells without any previous exposition to
exogenous TGF-b1 (Figure 5B). Moreover, NRP2 expression was
associated with an increase of TGF-b1 on HT29 cytoplasmic
membrane, while treatment of Colo320 with NRP2-siRNA
decreased membrane-bound TGF-b1 (Figure S5). To confirm
our hypothesis that NRP2 induces a constitutive activation of the
TGFb1 pathway, we used a TGF-b1 signaling reporter assay for






colorectal cancer cells. Compared to HT29
ctrl, HT29
NRP2 exhi-
bited an enhanced smad2/3 activity, as reported in the Figure 5C.
At the opposite, smad responsive luciferase expression is signifi-
cantly decreased in Colo320 cells treated by siRNA targeting
NRP2 compared to Colo320 cells treated by siRNA-control after
TGF-b1 stimulation. (Figure 5C) NRP2 exerts a co-stimulatory
effect of the TGF-b1 pathway in colorectal cancer cells.
Then, we characterized TGFRI and TGFRII expression on
HT29andColo320.Interestingly,while thekinasecontainingrecep-
tor, TGFRI, was expressed both on HT29 and Colo320, TGFRII,
known to bind TGF-b1, was not present on Colo320 (Figure 5D).
Combined with the inhibition of membrane-bound TGF-b1b y
NRP2 targeting siRNA (Figure S5), these results supported the
hypothesis of a direct binding activity of TGF-b1 by NRP2 leading
to smad2/3 phosphorylation in colorectal cancer cells.
To examine if NRP2 could directly bind active TGF-b1, we
studied the binding of TGF-b1 to NRP2-Fc by Surface Plasmon
Resonance (SPR). We showed that TGF-b1 can directly bind to
NRP2-Fc chips as well as VEGF165 (Figure 5E). BSA was used
as a negative control. Specific Interactions were highlighted by
checking the interactions on Fc-control chips (bevacizumab coated
chips) (data not shown). These results were confirmed in co-immu-
noprecipitation experiments, where TGFRI could be detected in
NRP2-targeted immunoprecipitation. (Figure 5F) Therefore, these
results provide evidences of a direct binding activity of NRP2 for
TGF-b1, leading to cooperation with TGFRI and subsequent
smad2/3 phosphorylation.
NRP2-induced EMT is TGF-b1 dependent
Since NRPs are non-tyrosine kinase receptor, NRP2 and
TGFRI are thought to cooperate in order to mediate smad
phosphorylation and subsequent induction of EMT. Then, the
next set of experiments was performed to examine if TGF-b1
pathway neutralization in NRP2 positive cells can reverse NRP2-
mediated EMT. For TGF-b1 pathway neutralization, we used two
pharmacological inhibitors of TGFRI, SD-208 and SB-431542.
SD-208 and SB-431542 are specific inhibitors of TGF-b super-
family type I receptors [40,41,42]. Treatment of NRP2 expressing
cells with variable doses of SB-431542 has been performed to
determine the concentrations of this inhibitor required to decrease
nuclear smad phosphorylation in HT29
NRP2. After sub-cellular
separation, levels of nuclear phosphorylated smad2 and nu-
clear total smad2/3 proteins were evaluated by western blotting.
Whereas only 10 mM of SB-431542 decreases the nuclear level of
phosphorylated Smad2 in Colo320 cancer cells, 50 mM of TGFRI
inhibitor decreased the nuclear level of phosphorylated Smad2 in
HT29
NRP2 cancer cells. (Figure 6A)
Then, we assessed the influence of TGFRI pharmacological
inhibition on vimentin and E-cadherin levels in NRP2 expressing
colorectal cancer cell lines. SB-431542 treatment decreased dose-
dependently vimentin expression in Colo320 and HT29
NRP2
cancer cells and even restored E-Cadherin levels in HT29
NRP2
underlying that TGFRI plays an essential role in the maintenance
of the EMT phenotype conferred by NRP2 (Figure 6B). However,
TGFRI inhibition had no influence on E-Cadherin expression in
Colo320 which constitutively not express this molecule. Moreover,
we could observe a decrease of Snail and Twist transcription factor
levels following exposition of HT29
NRP2 and Colo320 to the
TGFRI pharmacological inhibitor SB-431542 (Figure 6C). Then,
since nuclear localization of beta-catenin is frequently observed in
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transcriptional activator in HT29
NRP2 cells, after treatment by
increased doses of SB-431542, by confocal microscopy analysis. A
treatment with 50 mM of SB-431542 during 16 hours induced the
relocalization of beta-catenin at the membrane of tumor cells,
indicating that TGFRI activity neutralization can reverse EMT in
NRP2 expressing colorectal cancer cells. (Figure 6D) Mitotracker
staining was realized in order to assess potential cytotoxicity of the
SB-431542 treatment. No cytotoxicity was observed at any dose of
SB-431542 used. For fluorescence quantification, ratio of fluo-
rescence intensity was calculated in each condition. We observed a
decrease of the ratio of nuclear fluorescence/cytoplasm-membrane
fluorescence intensity after treatments with 50 mM of SB-431542
in HT29
NRP2 cells, confirming the relocalization of beta-catenin at
the membrane of the cells. (Figure 6D).
Moreover, we analyzed the effect of TGFRI kinase inhibi-
tion on colony formation in soft agar experiments. For this
purpose, Colo320 expressing NRP2 (Colo320
siRNA-ctrl) or treated
by siRNA targeting NRP2 (Colo320
siRNA-NRP2) were cultured in
soft agar with or without SD208, another pharmacological inhi-
bitor of TGFRI and in the presence or not of TGF-b1. The ability
of NRP2 to promote the formation of Colo320 colonies in soft
agar cultures was not observed in the presence of TGFRI phar-
macological inhibition, in presence or not of TGF-b1 (Figure S6).
Similar results were obtained with SB-431542 (data not shown).
Moreover, exposition to 10 ng/mL of TGF-b1 increased the
number of colonies of Colo320
siRNA-ctrl, whereas this treatment
had no impact on Colo320
siRNA-NRP2 cells. (Figure S6) These
experiments suggest that the EMT program mediated by NRP2
depends on TGF-b1.





siRNA-NRP2 by intra-cellular flow-cytometry. Relative Fluorescence Intensity (RFI) was calculated. B, Western-blotting experiments were
performed on nuclear extracts of HT29
ctrl and HT29
NRP2 cultured in serum free conditions or with 10 ng/mL of TGF-b1 for 16 hours. Histone-H1 was
used as a control of protein loading. Blotted proteins have been quantified with the BIO-1D advanced software and reported to the Histone-H1
level. While exogenous TGF-b1 is mandatory for smad2 phosphorylation detection in HT29, Smad2 is constitutively phosphorylated in HT29
NRP2
cells without any previous exposition to exogenous TGF-b1. C, TGF-b1 Cignal reporter assay kit was used for the quantification of TGF-b1-induced
smad2/3 signaling in HT29
ctrl,H T 2 9
NRP2, Colo320
siRNA-ctrl and Colo320
siRNA-NRP2 cells. An up-regulation of approximatively 17 times of the smad
response is observed in HT29
NRP2 cells compared to HT29
ctrl after TGF-b1 stimulation. At the opposite, smad dependent response is significantly
decreased in Colo320 cells treated by siRNA targeting NRP2 compared to Colo320 cells treated by siRNA-control after TGF-b1 stimulation. Results
are presented as the ratios between the firefly luciferase activity and the renilla luciferase activity (Ren/Luc) for each conditions. This experiment was





cells. Relative Fluorescence Intensity (RFI) was calculated. Colo320 cells don’t express TGFRII. E, Surface plasmon resonance studies were performed
to explore TGF-b1 interactions with NRP2. Fc-NRP2 proteins were covalently grafted on a chemically activated self assembled protein chip.
Injections of TGF-b1, BSA (Control -), VEGF (Control +) were performed at 250 nM in PBS-Tween 0.05%, before biacore analysis. These experiments
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PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e20444Altogether, these results suggest that NRP2 expression leads to
TGF-b1 constitutive signaling activation and sustains a possible
role of NRP2 and TGF-b1 in EMT. The oncogenic properties of
NRP2 and its direct involvement in EMT open new perspectives
to design specific targeted therapeutics.
Discussion
There is increasing evidence that epithelial-mesenchymal tran-
sition (EMT) is involved in cancer progression. For most car-
cinomas, cancer progression is correlated with a loss of epithelial
differentiation and a shift towards a mesenchymal phenotype.
This process, referred to as EMT, enhances motility and
invasiveness of many cell types and is often considered as a
prerequisite for tumor infiltration and metastasis. The targeting of
specific molecules involved in EMT is of particular interest to
prevent cancer progression. However, such specific therapies
interfering with the EMT process are still missing. Neuropilins
were initially described as kinase-deficient neuronal patterning
receptors recognizing class-3 semaphorin ligands. Indeed, neu-
ropilins have emerged as regulators of neuronal growth cone
collapse and cell motility mediated by semaphorins during
embryogenesiss [1] leading us to explore the hypothesis of their
involvement in EMT.
Figure 6. TGF-b1 is required for NRP2-mediated EMT. A, Western-blotting experiments were performed on nuclear extracts of HT29
NRP2 and
Colo320 for the detection of nuclear smad proteins after treatment with increased doses of TGFRI kinase-inhibitor SB-431542 (10 mM, 50 mM). DMSO is
the control medium. Histone-H1 was used as a control of protein loading. Whereas only 10 mM of SB-431542 decreases the nuclear level of
phosphorylated Smad2 in Colo320 cancer cells, doses of 50 mM should be used to decrease the nuclear level of phosphorylated Smad2 in HT29
NRP2
cancer cells. Smad proteins have been quantified with the BIO-1D advanced software and reported to the Histone H1 level. B, Overnight treatment with
increased doses of TGFRI kinase-inhibitor SB431542 (10 mM, 50 mM, 100 mM) inhibited dose-dependently vimentin expression in Colo320 and in
HT29
NRP2 cells. TGF-b1 signaling inhibition restored in part E-cadherin in HT29
NRP2 cells. Proteins have been quantified with the BIO-1D advanced
software and reported to the b-actin level. Data represent results of a representative experiment out of 3. C, Western-blotting experiment realized with
Colo320 and HT29
NRP2 whole cell lysates overnight treated with increased doses of TGFRI kinase-inhibitor SB431542 (10 mM, 50 mM, 100 mM). SB431542
treatment inhibited dose-dependently snail1 and twist1 expression in Colo320 and in HT29
NRP2 cells. Proteins have been quantified with the BIO-1D
advanced software and reported to the b-actin level. D, Confocal microscopy analysis of localization of b-catenin in HT29
NRP2 cells after overnight
treatment with increased doses of TGFRI kinase-inhibitor SB431542 (10 mM, 50 mM). Cells (HT29
NRP2) were stained with DAPI (blue) for nuclear staining,
with mitotracker (purple) for cytotoxicity dectection and also with an anti-b-catenin antibody (green). Mitotracker staining (purple) was realized in order
toassesspotentialcytotoxicityoftheSB-431542 treatment.Lossofstainingofthismarkercorrelateswithincreasedcytotoxicity.16hours treatment with
50 mM of SB-431542 induces relocalization of beta-catenin at the membrane of the cells, indicating that TGFRI activity neutralization by SB-431542 can
reverse EMT in HT29
NRP2 colorectal cancer cells. No cytotoxicity was observed at any dose of SB-431542 used. For fluorescence quantification, ratio of
fluorescence intensity was calculated in each condition. A decreased ratio of nuclear fluorescence/cytoplasm-membrane fluorescence intensity after
treatment with 50 mM of SB-431542 in HT29
NRP2 cells was observed indicating that beta-catenin relocalizes at the membrane of the cells.
doi:10.1371/journal.pone.0020444.g006
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identification of their implication in vascular and lymphatic
sprouting controlled by VEGF. The role of NRPs in vascular
development regulation supported their potential involvement in
cancer neo-angiogenesis. Blocking NRP1 in mice exposed to
cancer cells, resulted in a vascular-specific anti-tumor activity [44].
Based on the ability of NRP2 to bind VEGF-A, C and D, studies
were conducted to investigate the role of NRP2 in cancer neo-
vascularization. Neutralization of NRP2 in different tumor models
led to tumor lymphangiogenesis inhibition [5].
In addition to their expression on neovessels, NRPs have been
detected on several human tumors. The wide expression of NRPs
among different human tumors suggested a potential role of this
molecular network in cancer progression. Although the role of
NRP1 in cancer was largely demonstrated [45], the precise
contribution of NRP2 in oncogenesis was only recently considered.
A role for NRP2 in cancer cells has been initially suggested in colon
cancer. The first investigations showed that NRP2 is expressed on
human colon cancer cellswhile undetectable in uninvolved adjacent
mucosa [14]. NRP2 expression was shown to promote the malig-
nant phenotype of colon cancers [14], pancreatic cancers [15], and
breast cancers [18]. Particularly, NRP2 knock-down hampered
anchorage-independent growth in several tumor models [14,15].
Our results first confirmed the role of NRP2 in cancer
proliferation in vitro and xenograft formation in vivo (Figures 2
and 3). We also extended the understanding of NRP2 oncogenic
functions. We have shown that NRP2 is a critical component of
epithelial to mesenchymal transition. Analysis of NRP2 transfected
cell lines and NRP2 expressing xenografts established that NRP2-
expressing tumor cells displayed an immunohistochemical pheno-
type of EMT characterized by the loss of E-Cadherin and an
increase of vimentin expression (Figure 4).
EMT is a pivotal component of cancer invasiveness associated
with loss of epithelial differentiation and gain of mesenchyme-like
capabilities. Loss of homophilic cell adhesions and polarity is
widely associated with loss of functional E-cadherin and acquisi-
tion of proteins regulating cytoskeletal functions such as vimentin.
A direct role of vimentin in cancer invasiveness, when co-
expressed with keratins, was suggested in breast carcinoma cell
lines [46]. The expression of vimentin in invasive colorectal
carcinoma was not thoroughly investigated. Brabletz T et al
observed an expression of vimentin in colorectal cancer cell lines
and dedifferentiated human colorectal carcinoma [47]. The
association between vimentin and EMT in colorectal cancer cell
was confirmed in a recent study [48]. Of note, these authors
demonstrated that TGFb-1-mediated EMT directly drives vimen-
tin production in colon cancer cells [48].
However, in our study, treatment with recombinant TGF-b1
failed to induce vimentin expression or to decrease E-cadherin
level in HT29 cells (data not shown). In contrast, NRP2 transgenic
expression induced vimentin and repressed E-Cadherin in HT29.
Moreover, TGFRI pharmacological inhibition restored E-Cad-
herin expression, suggesting cooperation between TGFRI and
NRP2 signaling for EMT promotion. Co-immunoprecipitation
experiment confirmed that NRP2 interacts with TGFRI in colon
cancer cells. Furthermore, from these results it is postulated that
NRP2 expression might be an early component of EMT pro-
moting cadherin switch and acquisition of vimentin expression.
From our results it also appears that NRP2 induction is cor-
related to the transcription of the E-Cadherin repressors snail
and twist1, suggesting a direct role of NRP2 in EMT program
acquisition (Figure 4).
Moreover, a peptide (RKFK) of the b2 domain of NRP1, was
recently shown to be implicated in TGF-b1 binding [37].
Comparison of the amino acid sequences of NRP1 and NRP2
revealed that RKFK peptide is a conserved sequence of the
extracellular part of these receptors.
These observations prompted us to investigate the role of NRP2
on TGF-b1 signaling. Our work highlights a cross-talk between
NRP2 and TGF-b1 signaling to promote cancer progression. We
could observe that NRP2 gene transfer induces a constitutive
expression of activated Smad2/3 and a nuclear localization of
phospho-Smad2/3 complexes in HT29 (Figure 5A and 5B).
Moreover, NRP2 expression on colon cancer cell lines promoted
their capacities to respond to TGF-b1 (Figure 5).
Treatment of Colo320 cell lines with SD208 or SB431542,
two TGFR1 kinase inhibitors, abrogated the effect of NRP2 on
proliferation in colony formation in soft agar assays (Fig S6). More-
over, TGFRI-kinase inhibitors treatment decreases dose-depen-
dently NRP2-induced vimentin and restores in part E-Cadherin in
HT29
NRP2 cells, suggesting the requirement of TGFRI in NRP2-
induced EMT (Figure 6).
The precise role of the TGF-b1-activated Smads in EMT is
complex. While activated Smad2/3 complexes promote EMT, the
inhibitory Smad7 prevents the transition of cancer cells towards
a mesenchymal phenotype [49]. Interestingly, we observed a
reduced level of Smad7 in colon cancer cells following NRP2 gene
transfer (data not shown). This molecular feature might ac-
count for the enhanced colony and xenograft-formation capacities
associated with NRP2 expression.
A critical function in cancer cell survival was previously attri-
buted to NRP2 in colon cancer cells [14]. In this model, NRP2
sustains VEGFR1 activity leading to constitutive phosphorylation
of Akt and VEGF-mediated survival. Our results suggest the
presence of an alternative signaling pathway governed by NRP2
and triggering the Smad-dependent TGF-b1 signaling to initiate
the EMT process.
Since EMT is a critical step towards invasion and cancer
progression, these results suggest that NRP2 fulfills all the criteria
of a therapeutic target to disrupt multiple oncogenic functions in
solid tumors.
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siRNA-ctrl cells. Low level of VEGF-A was detected
and no significative difference in secretion of VEGF-A was noticed
in all cell lines analyzed. NRP2 expression did not influence VEGF
production.
(TIF)
Figure S2 Western blotting experiments showed that
HT29
ctrl and HT29
NRP2 express the same level of
semaphorin 3F, whereas no semaphorin 3F was found
in Colo320 cells. b-actin was used as a control of protein loading.
(TIF)
Figure S3 A, HT29
ctrl and HT29
NRP2 were cultured and
observed using a light microscope. Cells were photographed
at magnification *40. HT29
NRP2 displayed a fibroblastic-like shape
whereasHT29
ctrl exhibited a cuboidal phenotype. B, FACS analysis
reveals that NRP2 expression induces decrease of Epcam protein in
HT29
NRP2 cells. C, FACS analysis of NRP2 and Epcam proteins in
pancreatic cancer cell lines. NRP2 and Epcam are inversely cor-
related. (red: isotype, green: anti-NRP2 or anti-Epcam antibodies).
(TIF)
Figure S4 Western-blotting experiments shows that
NRP2 positive cells (Colo320
siRNA-ctrl and HT29
NRP2)
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was used as a control of protein loading.
(TIF)
Figure S5 The level of membrane associated-TGF-b1






cence Intensity (RFI) was calculated. NRP2 expression is
associated with an increase of TGF-b1 on HT29 cytoplasmic






cultured in soft-agar containing medium for 10 days
with or without TGFRI pharmacological inhibitor
(SD208, 10mMol). DMSO is the diluent of the TGFRI
pharmacological inhibitor SD208 and serves as control medium.
The ability of NRP2 to promote the formation of Colo320
colonies in soft agar cultures was not observed in the presence of
TGFRI pharmacological inhibition, in presence or not of TGF-b1.
10ng/mL TGF-b1 treatment increased the number of colonies of
Colo320
siRNA-ctrl, whereas this same treatment has no impact on
Colo320
siRNA-NRP2 cells. Data represent means of triplicates plus
or minus the standard error (SE). The presence of TGFRI
pharmacological inhibitor decreased the ability of Colo320 to
form colony in soft agar cultures.
(TIF)
Table S1 Review of the publications mentioning the
expression of NRP2 in cancer samples (x indicates the
identification of NRP expression, while ND (note done)
indicates the absence of investigation related to NRP1 or
2 expression in tumor cell lines.
(DOCX)
Table S2 NRP2 expression in tumor cell lines.
(DOCX)
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